WO2003097034A1 - Inhibiteurs de l'expression du tgf-$g(a) - Google Patents
Inhibiteurs de l'expression du tgf-$g(a) Download PDFInfo
- Publication number
- WO2003097034A1 WO2003097034A1 PCT/JP2003/006116 JP0306116W WO03097034A1 WO 2003097034 A1 WO2003097034 A1 WO 2003097034A1 JP 0306116 W JP0306116 W JP 0306116W WO 03097034 A1 WO03097034 A1 WO 03097034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tgf
- cells
- expression
- inhibitor according
- transformation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a transforming growth factor-a (TGF-a) comprising a polyprenyl compound as an active ingredient, which is sometimes referred to as "TGF- ⁇ " in the present specification.
- TGF-a transforming growth factor-a
- the present invention relates to an agent for suppressing expression, an agent for suppressing the transformation of hepatitis cells or cirrhosis cells by suppressing the expression, and an agent for suppressing the onset, recurrence (secondary carcinogenesis) or malignancy of liver cancer.
- HBV hepatitis I virus
- HCV hepatitis C virus
- liver cancer After treatment, liver cancer has a recurrence rate (secondary carcinogenesis) of about 20 to 25% annually, and is a disease with a poor prognosis. Therefore, as well as early detection and early treatment of liver cancer, important issues in the future include suppression of hepatocarcinogenesis from chronic hepatitis and suppression of recurrence after treatment for liver cancer.
- secondary carcinogenesis secondary carcinogenesis
- TGF-- Transforming growth factor-ct
- HGF-- Transforming growth factor-ct
- Hepatic TGF- ⁇ expression levels are related to the severity of inflammation in viral hepatitis, and overexpression of TGF- in cirrhosis caused by hepatitis virus is related to hepatitis virus replication.
- TGF- ⁇ is higher in liver tissue of patients with chronic liver disease caused by HBV and HCV infection than in healthy individuals.
- High expression of TGF- ⁇ is also observed in surrounding non-cancerous tissues, suggesting that TGF-a may play a crucial role in the process of hepatitis virus infection during the development and development of liver cancer. I have.
- liver cancer since TGF-a is deeply involved in hepatocarcinogenesis and malignancy of liver cancer cells, it has been proposed that a new therapeutic strategy for liver cancer targeting TGF- ⁇ will be established.
- hepatic stem cells oval cells: hereinafter sometimes referred to as oval cells in this specification. It has been pointed out that it may play an important role. In other words, it has been confirmed that oval cells proliferate in patients with chronic hepatitis or cirrhosis, and the number of oval cells increases as the liver lesions become more severe.
- hepatitis virus causes chronic inflammation in the liver and enhances the mitotic proliferation activity of oval cells, but hepatitis virus also acts on oval cells as a carcinogenic initiator. These findings suggest that oval cells initiated by the hepatitis virus have an enhanced mitotic proliferation activity (promotion) due to chronic inflammation and become cancerous (carcinogenesis).
- hepatocarcinogenesis experiments using animals have shown that hepatocellular carcinoma is derived from dedifferentiated hepatic cells, but that the phenotype of hepatocarcinoma cells is similar to oval cells. It has been pointed out that there is a possibility of hepatocarcinogenesis originating from oval cells.
- TGF- ⁇ is a mitogen in oval cells
- TGF- ⁇ produced in oval cells itself or in the surrounding liver and tissues is the epidermal growth factor receptor (epidermal). Stimulates oval cell growth via growth factor receptor (EGFR).
- EGFR growth factor receptor
- oval cells which are prominently observed in chronic viral hepatitis in humans, have been confirmed to be target cells for hepatitis virus infection and to be accompanied by increased expression of TGF- ⁇ . It is possible that the oval cells themselves may migrate to hepatocellular carcinoma cells by acting at the initial stage (initiation) and involving TGF-as a subsequent promoter.
- TGF- ⁇ which is overexpressed in hepatitis Z cirrhotic tissue around the oval cell, also promotes oval cell carcinogenesis via the receptor.
- TGF- ⁇ is closely associated with the transformation of hepatitis and cirrhosis cells, carcinogenesis in liver and malignant transformation of liver cancer cells, and is overexpressed in liver tissue cells and oval cells in liver Controlling TGF- ⁇ in a state is likely to lead to suppression of transformation of hepatitis and cirrhosis cells, and suppression of carcinogenesis in liver and malignancy of liver cancer cells.
- NIK- 333 polyprenyl compounds
- polyprenyl compounds suppress the expression of TGF- a in established hepatoma cells (Reference: Biochem. Biophys. Res. Commun. 219, 100-104 (1996)).
- polyprenyl compounds inhibit TGF-a in living liver fibroblasts by the administration of a hepatic chemical carcinogen, and suppress TGF-a in oval cells, which are considered to be precursor cells of liver cancer. It is not known at all to suppress ⁇ expression. Disclosure of the invention
- an object of the present invention is to provide an agent for suppressing the transformation of hepatitis and Z or cirrhosis cells by suppressing the expression of TGF-a, an agent for suppressing carcinogenesis in the liver and an agent for suppressing cancer malignancy. is there.
- the present inventors have been conducting various studies to find a transformation inhibitor of hepatitis and / or cirrhosis cells (a malignant inhibitor of hepatitis or cirrhosis), and an inhibitor of carcinogenesis and cancer malignancy in the liver.
- a transformation inhibitor of hepatitis and / or cirrhosis cells a malignant inhibitor of hepatitis or cirrhosis
- an inhibitor of carcinogenesis and cancer malignancy in the liver was.
- polyprenyl compounds suppressed the expression of TGF-a in hepatic tissue cells transformed with hepatocarcinogens, and TGF- in oval cells has been strongly suggested as a potential precursor of hepatocellular carcinoma.
- the inventors have found that the expression of sperm is suppressed, and have completed the present invention.
- the present invention relates to a TGF- a expression inhibitor comprising a polyprenyl compound as an active ingredient, and a hepatitis and / or cirrhosis cell transformation inhibitor comprising a polyprenyl compound as an active ingredient (hepatitis or It is an agent for suppressing malignant transformation of cirrhosis). Furthermore, the present invention relates to an agent for suppressing the transformation of hepatitis cells or cirrhosis cells by suppressing the expression of TGF-a, which contains a polyprenyl compound as an active ingredient, and for controlling the onset, recurrence (secondary carcinogenesis), or malignancy of liver cancer. It relates to inhibitors.
- the present invention provides a method for suppressing the transformation of hepatitis cells or cirrhosis cells by suppressing the expression of TGF-a in a mammal, including a human, using the polyprenyl compound for the production of the above-mentioned medicament, And a method for suppressing carcinogenesis or malignant transformation of cancer cells in the liver by suppressing the expression of TGF-H, which comprises the step of administering an effective amount of a polyprenyl compound to mammals including humans; and hepatitis cells or liver.
- a method for inhibiting the transformation of cirrhotic cells, and the onset and recurrence of cancer in the liver are examples of cancer in the liver.
- the present invention provides a method comprising the step of administering to a mammal an inhibitory effective amount of a polyprenyl compound.
- FIG. 1 shows a photograph of the liver tissue of an untreated animal. No expression of oval cells showing TGF-a positivity was observed at all.
- -Fig. 2 shows that oval cells expressed in the liver tissue of the control group (administered only with the hepatic carcinogen 3'-MeDAB) showed strong TGF-a-positive findings in the cytoplasm (dark brown stained areas indicate TGF-a (Indicating that has occurred).
- Fig. 3 shows that oval cells expressed by 3
- -MeDAB showed weak TGF- ⁇ positivity after administration of NIK-333 at 80 mg / kg / day (the dark brown staining was smaller than in Fig. 2).
- 4) is a photograph showing that TGF-a expression is reduced.
- FIG. 4 shows a photograph of liver tissue of an untreated animal. Almost no expression of TGF-a was observed.
- FIG. 5 is a photograph showing TGF- ⁇ expression in non-tumorous liver tissue of a control group (administered only with the hepatic chemical carcinogen DEN).
- DEN hepatic chemical carcinogen
- FIG. 7 shows a photograph of the liver and tissue of an untreated animal. The expression of TGF- ⁇ is hardly observed.
- FIG. 8 is a photograph showing TGF-a expression in non-tumor liver tissue of a control group by DEN administration. A strong positive finding of TGF- ⁇ is observed in the liver tissue around the central vein (dark brown staining indicates that TGF- ⁇ is expressed).
- FIG. 9 shows an image in which TGF- ⁇ expressed in liver tissue around the central vein by DEN was almost negative after administration of ⁇ -333 at 80 mg / kg / day (the dark brown stained portion was hardly seen). It is a photograph showing (shown).
- FIG. 10 shows a photograph of the liver tissue of an untreated animal. No expression of oval cells showing TGF- ⁇ positivity was observed.
- Fig. 11 shows that oval cells expressed in the liver tissue of the control group by 3'-MeDAB administration show strong TGF- ⁇ positive findings in the cytoplasm (the dark brown stained portion expresses TGF- ⁇ ) It is a photograph showing.
- Fig. 12 shows that the number of oval cells positive for TGF- ⁇ expressed by 3'-MeDAB was reduced by NIK-333 at 80 mg / kg / day (cells stained dark brown). Is smaller than that of FIG. 11).
- FIG. 13 shows photographs of the moon-dried tissues of untreated animals. No cells showing clear TGF-positive findings are found.
- Fig. 14 shows images of oval cell force S expressed in the liver tissue of the control group by administration of D-galactosamine hydrochloride, and strong TGF- ⁇ positive findings in the cytoplasm (the dark brown stained portion indicates that TGF- was expressed. It is a photograph showing.
- Fig. 15 shows images of TGF-a weakly positive after administration of 200 mg / kg / day of oval cell force NIK-333 expressed by D-galactosamine hydrochloride (the dark brown stained area is smaller than in Fig. 14 FIG. Indicates that TGF-a expression is reduced.
- the polyprenyl compounds used in the present invention include 3,7,11,15-tetramethyl-2,4,6,10,14-hexadenic pentaenoic acid, which is a polyprenylcarboxylic acid, and gerani olelegeranoic acid (GGA Geranyl geranoic acid, phytanic acid and the like; and polyprenyl carboxylate, vitamin Kl, vitamin ⁇ 2 and the like.
- Preferred compounds include polyprenyl carboxylic acids, especially 3,7,11,15-tetramethyl-2,4,6,10,14-hexadenic pentaenoic acid, and most preferred compounds (2E, 4E, 6E, 10E) -3,7,11,15-Tetramethyl-2,4,6,10,14-Hexadenic pentaenoic acid (NIK-333).
- the polyprenyl compound used in the present invention can be synthesized by a known method (Japanese Patent Publication No. 63-32058, J. Chem. Soc. (C), Item 2154, 1966).
- the TGF_a expression inhibitor of the present invention can be usually prepared as a pharmaceutical composition containing a polyprenyl compound, and administered by an oral or parenteral administration method.
- Pharmaceutical compositions suitable for oral administration include, for example, tablets, granules, capsules, soft capsules, pills, powders, and liquids.
- Examples of the pharmaceutical composition suitable for parenteral administration include: For example, injections, suppositories and the like can be mentioned.
- These pharmaceutical compositions can be prepared by a conventional method using a polyprenyl compound or a pharmacologically acceptable salt thereof and one or more ordinary pharmaceutical carriers.
- excipients such as lactose, glucose, corn starch, and sucrose
- disintegrants such as calcium lipoxymethylcellulose and hydroxypropylcellulose; calcium stearate
- Lubricants such as magnesium stearate, talc, polyethylene glycol, hydrogenated oil, etc., hydroxypropinoresenolerose, hydroxypropyl methylcellulose, propyloxymethinolecellulose, polyvinylinoleanolonecorne, gelatin, gum arabic
- a desired pharmaceutical composition can be prepared by using a binder such as glycerin and ethylene glycol, a surfactant, a flavoring agent, and the like, if necessary.
- a diluent such as water, ethanol, glycerin, propylene glycol, polyethylene glycol, vegetable oil, agar, or tragarant gum as a pharmaceutical carrier, and dissolve as necessary.
- Agents, suspending agents, emulsifiers, stabilizers, buffers, isotonic agents, preservatives, soothing agents and the like can be used.
- the dose of the TGF- ⁇ expression inhibitor of the present invention is not particularly limited.For example, 50 to 1200 mg, preferably 300 to 900 mg per day for an adult per day, and 1 to 1 day per day for a parenteral. The range is 1200 mg, preferably 5 to 900 mg. A desired inhibitory effect can be expected by administering each of the above doses once to three times a day.
- the animals used were Fischer male rats (F344 / N Slc, 6 weeks old).
- the liver chemical carcinogen 3'-MeDAB was administered to a solid feed at a ratio of 0.06% for 4 weeks.
- NIK-333 was suspended in soybean oil and orally administered at a dose of 80 mg / kg in parallel with 3'-MeDAB for 4 weeks (once / day).
- the control group was orally administered with soybean oil (5 mL / kg).
- the liver was removed under anesthesia, fixed in 10% formalin, embedded in paraffin, immunohistochemically stained with anti-TGF-antibody, and examined for the degree of TGF- ⁇ expression under a microscope. Was observed.
- Figures 1 to 3 show suppression of TGF-a-positive oval cell induction induced by 3, -MeDAB for 4 weeks when NIK-333 was administered simultaneously with 80 mg / kg / day of NIK-333 for 4 weeks It is a photograph showing the effect (immunohistological staining with anti-TGF- ⁇ antibody). Similar findings have been obtained in other animals that were performed at the same time.
- FIG. 1 shows the liver tissue of an untreated animal. No expression of oval cells showing TGF- ⁇ positivity was observed at all.
- FIG. 2 shows strong TGF- ⁇ positive findings in cytoplasm in oval cells expressed in liver tissue of a control group (only 3′-MeDAB was administered).
- FIG. 3 shows that oval cells expressed by 3, -MeDAB show weak TFG- a positivity and decrease TGF- ⁇ expression when NIK-333 is administered at 80 mg / kg / day.
- FIG. 10 shows the liver tissue of an untreated animal. Expression of oval cells showing TGF-positive is not observed.
- FIG. 11 shows strong TGF-a positive findings in the cytoplasm of oval cells expressed in the liver tissue of the control group by 3, -MeDAB administration.
- FIG. 12 shows that the number of oval cells positive for TGF- ⁇ expressed by 3, -MeDAB was reduced by NIK-333 80 mg / kg / day administration.
- NIK-333 was suspended in soybean oil and orally administered at a dose of 80 mg / kg for 14 weeks (once / day) one week after the end of DEN administration.
- the control group was orally administered with soybean oil (5 mL / kg).
- the liver was removed under anesthesia, fixed in 10% formalin, embedded in paraffin, immunized with anti-TGF-H antibody, and stained with TGF- ⁇ to determine the level of TGF- ⁇ expression. Observed under a microscope.
- Fig. 4 to Fig. 6 show suppression of TGF-a expression in non-tumorous liver tissue when DEN is treated for 5 weeks with 5-week treatment, followed by NIK-333 80 mg / kg / day for 14 weeks.
- 4 is a photograph showing the effect (immunohistological staining with anti-TGF- ⁇ antibody). Similar findings have been obtained in other animals that were performed at the same time.
- FIG. 4 shows the liver tissue of an untreated animal. The expression of TGF- ⁇ is hardly observed.
- FIG. 5 shows TGF-expression in non-tumor liver tissues of a control group (administered only with DEN). Liver tissue around the central vein is strongly positive for TGF-a.
- FIG. 6 shows the results that TGF- ⁇ expressed in liver tissue around the central vein by DEN was almost negative by NIK-333 80 mg / kg / day administration.
- FIG. 7 shows the liver tissue of an untreated animal. Almost no expression of TGF-a is observed.
- FIG. 8 shows TGF- ⁇ expression in non-tumor liver tissues of a control group by DEN administration. Liver tissue around the central vein is strongly positive for TGF-.
- Fig. 9 shows TGF-power S, NIK-333 expressed in liver tissue around the central vein by DEN.
- the animals were male SD rats (Crj / CD (SD), 6 weeks old), intraperitoneally administered once with 5 mL / kg of D-galactosamine hydrochloride adjusted to 200 mg / mL with physiological saline, and oval cells were administered. I was invited.
- NIK-333 was suspended in soybean oil and administered orally at a dose of 200 mg / kg for 1-6 days.
- the control group was orally administered soybean oil (2 mL / kg).
- the liver was removed under anesthesia over time from the day after the start of dosing to the 7th day under anesthesia, fixed in 10% formalin, embedded in paraffin, immunohistochemically stained with anti-TGF- ⁇ antibody, and expressed TGF- ⁇ . was observed under a microscope.
- Figures 13 to 15 show the results of administration of 200 mg / kg / day of ⁇ -333 for 4 days against the expression of TGF- ⁇ in oval cells induced by a single administration of D-galactosamine hydrochloride.
- 5 is a photograph showing the inhibitory effect of immunohistochemistry (immunohistological staining with anti-TGF- ⁇ antibody). Similar findings have been obtained in other animals that were performed at the same time.
- FIG. 13 shows the liver tissue of an untreated animal. No cells showing clear TGF-C positive findings are found.
- FIG. 14 shows the results of strong TGF-o; positive in the cytoplasm of oval cells expressed in the liver tissue of the control group by administration of D-galactosamine hydrochloride.
- FIG. 15 shows the results in which TGF- ⁇ expression was weakly positive and TGF- ⁇ expression was reduced by administration of 200 mg / kg / day of oval cell force NIK-333 expressed by D-galactosamine hydrochloride.
- Polyprenyl compounds suppress the transformation of hepatitis cells or cirrhosis cells or TGF- ⁇ involved in carcinogenesis or malignant transformation of cancer cells in the liver. It can be used as an inhibitor of malignant transformation of hepatitis cells or cirrhosis, and is useful as an inhibitor of the onset, recurrence (secondary carcinogenesis), or malignancy of liver cancer.
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004505033A JPWO2003097034A1 (ja) | 2002-05-17 | 2003-05-16 | TGF−α発現抑制剤 |
KR1020107007357A KR20100041891A (ko) | 2002-05-17 | 2003-05-16 | 간염세포 및/또는 간경변 세포의 형질전환을 억제하는 간암 예방제 |
KR10-2004-7018530A KR20050024274A (ko) | 2002-05-17 | 2003-05-16 | TGF-α 발현 억제제 |
EP03752675.3A EP1506778B1 (en) | 2002-05-17 | 2003-05-16 | TGF-a EXPRESSION INHIBITORS |
AU2003234925A AU2003234925A1 (en) | 2002-05-17 | 2003-05-16 | TGF-Alpha EXPRESSION INHIBITORS |
US10/513,784 US20060094784A1 (en) | 2002-05-17 | 2003-05-16 | Tgf-alpha expression inhibitors |
ES03752675.3T ES2470369T3 (es) | 2002-05-17 | 2003-05-16 | Inhibidores de la expresión de TGF-a |
US12/230,137 US20090069424A1 (en) | 2002-05-17 | 2008-08-25 | TGF-alpha expression inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002142862 | 2002-05-17 | ||
JP2002-142862 | 2002-05-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/230,137 Division US20090069424A1 (en) | 2002-05-17 | 2008-08-25 | TGF-alpha expression inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003097034A1 true WO2003097034A1 (fr) | 2003-11-27 |
Family
ID=29545001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/006116 WO2003097034A1 (fr) | 2002-05-17 | 2003-05-16 | Inhibiteurs de l'expression du tgf-$g(a) |
Country Status (8)
Country | Link |
---|---|
US (2) | US20060094784A1 (ja) |
EP (1) | EP1506778B1 (ja) |
JP (2) | JPWO2003097034A1 (ja) |
KR (2) | KR20050024274A (ja) |
CN (1) | CN100428932C (ja) |
AU (1) | AU2003234925A1 (ja) |
ES (1) | ES2470369T3 (ja) |
WO (1) | WO2003097034A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314643B2 (en) | 2002-08-20 | 2008-01-01 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
WO2008126363A1 (ja) * | 2007-03-30 | 2008-10-23 | Kowa Company, Ltd. | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
US7547730B2 (en) | 2000-04-24 | 2009-06-16 | Kowa Company, Ltd. | Activators of peroxisome proliferator-activated receptors |
JP2010189446A (ja) * | 2002-05-17 | 2010-09-02 | Kowa Pharmaceutical Co Ltd | 肝臓癌の発症予防のための医薬 |
WO2011135743A1 (ja) * | 2010-04-28 | 2011-11-03 | 興和株式会社 | C型肝炎の予防及び/又は治療のための医薬 |
JP2011219438A (ja) * | 2010-04-14 | 2011-11-04 | Tottori Univ | レチノイン酸受容体リガンドの抗腫瘍作用、発癌抑制作用を含めた種々の作用を決定する遺伝子の同定 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
EP1660071A1 (en) | 2003-08-18 | 2006-05-31 | Btg International Limited | Treatment of neurodegenerative conditions |
GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
WO2008155920A1 (ja) | 2007-06-21 | 2008-12-24 | Josai University Corporation | 肝細胞増殖促進作用を有する医薬 |
JP5925767B2 (ja) * | 2011-04-27 | 2016-05-25 | 興和株式会社 | ホスホノクロトン酸誘導体の製造方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US250671A (en) * | 1881-12-13 | Mugilage-holder | ||
US63838A (en) * | 1867-04-16 | Sylvania | ||
JPS56140949A (en) * | 1980-04-07 | 1981-11-04 | Eisai Co Ltd | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenic acid |
JPS5731615A (en) * | 1980-07-31 | 1982-02-20 | Eisai Co Ltd | Remedy for skin disease with keratinization |
JPS57106638A (en) * | 1980-12-24 | 1982-07-02 | Eisai Co Ltd | Conjugated polyprenylcarboxylic acid and its derivative |
JPS58225039A (ja) * | 1982-06-22 | 1983-12-27 | Eisai Co Ltd | ポリプレニル系化合物 |
JPS6122054A (ja) * | 1984-05-09 | 1986-01-30 | Eisai Co Ltd | ポリプレニル系化合物 |
JPH0629218B2 (ja) * | 1985-03-15 | 1994-04-20 | エーザイ株式会社 | ポリプレニル系化合物 |
US4841038A (en) * | 1986-06-02 | 1989-06-20 | Wisconsin Alumni Research Foundation | Method for preparing coenzyme a esters of all-trans- and 13-cis retinoic acids |
US4757140A (en) * | 1986-06-02 | 1988-07-12 | Wisconsin Alumni Research Foundation | Coenzyme a derivatives of all-trans- and 13-cis retionic acid |
JPH10167960A (ja) * | 1996-12-12 | 1998-06-23 | Les-Bell:Kk | 肝細胞ガン再発抑制剤 |
AU737983B2 (en) * | 1996-12-12 | 2001-09-06 | Pharmacia & Upjohn Company | An oil composition of dihydropolyprenols |
CA2306525C (en) * | 1999-04-23 | 2009-06-23 | Nikken Chemicals Co., Ltd. | Method for purification of polyprenyl compounds |
EP1277469B1 (en) * | 2000-04-24 | 2010-05-05 | Kowa Company, Ltd. | Activators for peroxisome proliferator-activated receptor |
WO2003097034A1 (fr) * | 2002-05-17 | 2003-11-27 | Nikken Chemicals Co., Ltd. | Inhibiteurs de l'expression du tgf-$g(a) |
US6984742B2 (en) * | 2003-04-18 | 2006-01-10 | Nikken Chemicals Co., Ltd. | Method for preparing polyprenyl compounds |
-
2003
- 2003-05-16 WO PCT/JP2003/006116 patent/WO2003097034A1/ja active Application Filing
- 2003-05-16 ES ES03752675.3T patent/ES2470369T3/es not_active Expired - Lifetime
- 2003-05-16 US US10/513,784 patent/US20060094784A1/en not_active Abandoned
- 2003-05-16 EP EP03752675.3A patent/EP1506778B1/en not_active Expired - Fee Related
- 2003-05-16 CN CNB038111799A patent/CN100428932C/zh not_active Expired - Fee Related
- 2003-05-16 AU AU2003234925A patent/AU2003234925A1/en not_active Abandoned
- 2003-05-16 KR KR10-2004-7018530A patent/KR20050024274A/ko active Search and Examination
- 2003-05-16 JP JP2004505033A patent/JPWO2003097034A1/ja not_active Withdrawn
- 2003-05-16 KR KR1020107007357A patent/KR20100041891A/ko active Search and Examination
-
2008
- 2008-08-25 US US12/230,137 patent/US20090069424A1/en not_active Abandoned
-
2010
- 2010-06-09 JP JP2010131603A patent/JP2010189446A/ja active Pending
Non-Patent Citations (7)
Title |
---|
DI BISCEGLIE A.M.: "Hepatocellular carcinoma", HEPATOLOGY, vol. 28, no. 4, 1998, pages 1161 - 1165, XP002969929 * |
ISHIWARI K.: "Effects of a synthetic retinoid, polyprenoic acid (E5166), on phenotypic expression of cultured mesangial cells", KYOTO-FURITSU IKA DAIGAKU ZASSHI, vol. 106, no. 3, 1997, pages 273 - 283, XP002969930 * |
MUTO Y. ET AL.: "Antitumor activity of a novel synthetic compound polyprenoic-acid derivative", DERMATOLOGICA, vol. 169, no. 4, 1984, pages 241 |
MUTO Y.: "Chemoprevention of heptoma with polyprenoic acids", SYMPOSIA AND FREE COMMUNICATIONS, vol. 1, 2, 3, 1986, pages 847 |
MUTO Y.: "Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 334, no. 24, 1996, pages 1561 - 1567, XP000884177 * |
NAKAMURA N.: "Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 219, no. 1, 1996, pages 100 - 104, XP002969927 * |
OKUNO M.: "Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-<SYM98> in liver stellate cells", HEPATOLOGY, vol. 26, no. 4, 1997, PHILADELPHIA, pages 913 - 921, XP002969928 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7547730B2 (en) | 2000-04-24 | 2009-06-16 | Kowa Company, Ltd. | Activators of peroxisome proliferator-activated receptors |
US8017652B2 (en) | 2000-04-24 | 2011-09-13 | Kowa Company Ltd. | Activators of peroxisome proliferator-activated receptors |
JP2010189446A (ja) * | 2002-05-17 | 2010-09-02 | Kowa Pharmaceutical Co Ltd | 肝臓癌の発症予防のための医薬 |
US7314643B2 (en) | 2002-08-20 | 2008-01-01 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
WO2008126363A1 (ja) * | 2007-03-30 | 2008-10-23 | Kowa Company, Ltd. | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
JP2013216679A (ja) * | 2007-03-30 | 2013-10-24 | Kowa Co | 非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
JP5341749B2 (ja) * | 2007-03-30 | 2013-11-13 | 興和株式会社 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
US8673976B2 (en) | 2007-03-30 | 2014-03-18 | Kowa Company, Ltd. | Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis |
CN101652134B (zh) * | 2007-03-30 | 2015-07-15 | 兴和株式会社 | 用于预防和/或治疗脂肪肝或非酒精性脂肪性肝炎的药物 |
JP2011219438A (ja) * | 2010-04-14 | 2011-11-04 | Tottori Univ | レチノイン酸受容体リガンドの抗腫瘍作用、発癌抑制作用を含めた種々の作用を決定する遺伝子の同定 |
WO2011135743A1 (ja) * | 2010-04-28 | 2011-11-03 | 興和株式会社 | C型肝炎の予防及び/又は治療のための医薬 |
Also Published As
Publication number | Publication date |
---|---|
CN1652764A (zh) | 2005-08-10 |
JP2010189446A (ja) | 2010-09-02 |
CN100428932C (zh) | 2008-10-29 |
EP1506778B1 (en) | 2014-03-26 |
AU2003234925A1 (en) | 2003-12-02 |
KR20100041891A (ko) | 2010-04-22 |
EP1506778A1 (en) | 2005-02-16 |
JPWO2003097034A1 (ja) | 2005-09-15 |
EP1506778A4 (en) | 2009-12-16 |
US20090069424A1 (en) | 2009-03-12 |
ES2470369T3 (es) | 2014-06-23 |
KR20050024274A (ko) | 2005-03-10 |
US20060094784A1 (en) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010189446A (ja) | 肝臓癌の発症予防のための医薬 | |
US8501806B2 (en) | Methods for preventing or reducing colon carcinogenesis | |
JP6516341B2 (ja) | Nash関連肝臓癌を治療するためのep4受容体拮抗薬の使用 | |
CN111182904A (zh) | 包含acc抑制剂的组合治疗 | |
JP6490097B2 (ja) | 脂肪肝疾患の予防又は治療用組成物 | |
EP2222297A1 (en) | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition | |
TW201912153A (zh) | 用於治療b型肝炎的化合物、醫藥組合物及方法 | |
US10736902B2 (en) | Method of treating triple negative breast cancer | |
CN112138024A (zh) | 治疗严重形式的肺动脉高压的方法 | |
JP2021522345A (ja) | 新規なmct4阻害剤及びその使用 | |
JP5289310B2 (ja) | 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤 | |
WO2007018278A1 (ja) | 肝癌発生・進展抑制剤 | |
JP5792322B2 (ja) | ビタミンdおよびメトホルミン含有医薬組成物 | |
WO2011047595A1 (zh) | 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用 | |
JP6464277B2 (ja) | ネクロックスを有効成分として含有する粘膜炎予防又は治療用組成物 | |
WO2020218562A1 (ja) | 治療抵抗性がんの予防又は治療用の医薬組成物 | |
JP2001261555A (ja) | 脳動脈中膜肥厚抑制剤 | |
US20160175310A1 (en) | Boosting the effect of methotrexate through the combined use with lipophilic statins | |
WO2014172857A1 (zh) | 阿可拉定在制备用于治疗原发性肝癌的药物中的用途 | |
TWI834868B (zh) | 難治性癌症之預防或治療用之醫藥組合物 | |
KR20230127990A (ko) | 암 예방에서 단쇄 지방산의 용도 | |
CA3153784A1 (en) | Combination therapy having antioxydant properties | |
CN110719780A (zh) | 用于治疗nash和用于预防nash诱导的hcc的方法 | |
JP2003055207A (ja) | 癌転移抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004505033 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018530 Country of ref document: KR Ref document number: 20038111799 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003752675 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003752675 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018530 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006094784 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10513784 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10513784 Country of ref document: US |